Abstract: The semaphorin family contains a large number of plylogenetically conserved proteins and includes several members that have been shown to function in repulsive axon guidance. Semaplorin III (Sema III) is a secreted protein that in vitro causes neuronal growth cone collapse and chemorepulsion of neurites, and is required in vivo for correct sensory afferent innervation and other aspects of development. The mechanism of Sema III function, however, is unknown. Here, we report that neuropilin, a type I transmembrane protein, is a Sema III receptor. We also describe the identification of neuropiln-2, a related neuropilin family member, and show that neuropilin and neuropilin-2 are expressed in overlapping, yet distinct, populations of neurons in the rat embryonic nervous system.
Abstract: This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.
Type:
Grant
Filed:
September 29, 1999
Date of Patent:
July 16, 2002
Assignee:
Synaptic Pharmaceutical Corporation
Inventors:
Christophe Gerald, Mary W. Walker, Theresa Branchek, Richard L. Weinshank
Abstract: Methods of treating and/or prophylaxis Alzheimer's disease by preventing the formation of cerebral amyloid due to the growth and disruption of dense microspheres (DMS) are disclosed utilizing medicaments that are effective in preventing or inhibiting the growth and disruption of DMS.
Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of ≦10 nM of CRF occupy ≧50% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. Invention CRF-Rs can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
June 4, 2002
Assignee:
The Salk Institute for Biological Studies
Inventors:
Marilyn H. Perrin, Ruoping Chen, Kathy A. Lewis, Wylie W. Vale, Jr., Cynthia J. Donaldson, Paul Sawchenko
Abstract: Disclosed herein is a method of determining whether a first protein is capable of physically interacting with a second protein, involving: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including the first protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the second protein covalently bonded to a gene activating moiety and being conformationally-constrained; and (b) measuring expression of the reporter gene as a measure of an interaction between the first and the second proteins. Also disclosed are methods for assaying protein interactions, and identifying antagonists and agonists of protein interactions.
Type:
Grant
Filed:
April 9, 1996
Date of Patent:
June 4, 2002
Assignee:
The General Hospital Corporation
Inventors:
Roger Brent, John M. McCoy, Timm H. Jessen, Chanxing Wilson Xu
Abstract: Compositions for use in targeting therapies to central nervous system (CNS) cells are provided. The compositions comprise peptides which are capable of binding CNS cells in vivo.
Type:
Grant
Filed:
November 10, 1999
Date of Patent:
June 4, 2002
Assignee:
Auburn University
Inventors:
Bruce F. Smith, Tatiana I. Samoilova, Henry J. Baker
Abstract: Human protein C and activated protein C were shown to bind to endothelium specifically, selectively and saturably (Kd=30 nM, 7000 sites per cell) in a Ca2+ dependent fashion. Expression cloning revealed a 1.3 kb CDNA that coded for a novel type I transmembrane glycoprotein capable of binding protein C. This protein appears to be a member of the CD1/MHC superfamily. Like thrombomodulin, the receptor involved in protein C activation, the endothelial cell protein C receptor (EPCR) function and message are both down regulated by exposure of endothelium to TNF. Identification of EPCR as a member of the CD1/MHC superfamily provides insights into the role of protein C in regulating the inflammatory response, and determination of methods for pharmaceutical use in manipulating the inflammatory response.
Abstract: Antimicrobial compounds and compositions and uses thereof, including the treatment and prevention of bacterial infections are described. The compounds and compositions include lantibiotic polypeptides and the nucleic acid sequences encoding the polypeptides. The compounds and compositions are useful as antimicrobials in antibiotic pharmaceutical preparation and as an antimicrobial or antiseptic dentifrice.
Type:
Grant
Filed:
July 27, 1999
Date of Patent:
May 21, 2002
Assignee:
University of Florida Research Foundation, Inc.
Abstract: The present invention relates to a isolated leukaemia inhibitory factor (LIF)-binding protein (LBP) in soluble form and obtainable from a first mammalian species, said LBP capable of inhibiting the ability of LIF from a second mammalian species to induce differentiation of M1 myeloid leukaemic cells in vitro to a greater extent when compared to its ability to inhibit LIF from said first mammalian species.
Type:
Grant
Filed:
November 10, 1994
Date of Patent:
May 14, 2002
Assignee:
Amrad Corporation Limited
Inventors:
Nicos Anthony Nicola, Meredith Layton, Donald Metcalf, Richard J Simpson
Abstract: The nucleotide and deduced amino acid sequences of the four variable domains of the major outer membrane proteins of the 15 serovars of Chlamydia trachomatis are disclosed together with sequence and immunogenic analysis of these domains.
Type:
Grant
Filed:
February 9, 1999
Date of Patent:
May 7, 2002
Assignee:
The United States of America as represented by the Department
of Health and Human Services
Inventors:
Harlan D. Caldwell, Yuan Ying, You-Xun Zhang, Nancy G. Watkins
Abstract: The invention provides prfC polypeptides and DNA (RNA) encoding prfC polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing prfC polypeptides to screen for antibacterial compounds.
Abstract: The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.
Type:
Grant
Filed:
October 24, 1994
Date of Patent:
April 16, 2002
Assignee:
Baylor College of Medicine
Inventors:
James R. Smith, David J. Drutz, Deborah R. Wilson, Louis A. Zumstein
Abstract: Provided are animal host cells not naturally capable of forming secretory granules and that produce active, mature insulin by expression of a variant proinsulin containing a non-naturally occurring cleavage site and enzymatic cleavage of the non-naturally occurring cleavage site in the host cells. Further provided are methods of culturing such cells.
Type:
Grant
Filed:
March 1, 1993
Date of Patent:
February 19, 2002
Assignee:
Genentech, Inc.
Inventors:
Cornelia M. Gorman, Debyra J. Groskreutz
Abstract: A novel class of proteins, semaphorins, nucleic acids encoding semaphorins, semaphorin peptides, and methods of using semaphorins and semaphorin-encoding nucleic acids are disclosed. Semaphorin peptides and receptor agonists and antagonists provide potent modulators of nerve cell growth and regeneration. The invention provides pharmaceutical compositions, methods for screening chemical libraries for regulators of cell growth/differentiation; semaphorin gene-derived nucleic acids for use in genetic mapping, as probes for related genes, and as diagnostic reagents for genetic neurological disease; specific cellular and animal systems for the development of neurological disease therapy.
Type:
Grant
Filed:
April 15, 1998
Date of Patent:
February 5, 2002
Assignee:
The Regents of the University of California
Inventors:
Corey S. Goodman, Alex L. Kolodkin, David Matthes, David R. Bentley, Timothy O'Connor
Abstract: NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.
Type:
Grant
Filed:
April 25, 1997
Date of Patent:
December 25, 2001
Assignee:
Genentech, Inc.
Inventors:
Leonard G. Presta, Roman Urfer, John W. Winslow
Abstract: Strains of Leishmanda and other macrophage-infecting parasites are provided which express the GM-CSF gene which are useful in treating hosts infected by the parasite and in protecting hosts against disease caused by infection of hosts by parasites. The parasites are reduced in their ability to infect or survive in macrophages and hence are attenuated. At least one gene of the parasite contributing to the virulence thereto may be functionally disabled. The attenuated strains may be used for administration to a host (a) to treat a host infected by Leishmania or (b) to confer protection against disease caused by a virulent Leishmania strain, or as a diagnostic reagent.
Type:
Grant
Filed:
September 13, 1996
Date of Patent:
December 18, 2001
Assignee:
Universite Laval
Inventors:
Barbara Papadopoulou, Marc Ouellette, Martin Olivier
Abstract: This invention presents improved methodology for identification of nucleated cells in flow cytometric analysis when immunofluorescent dyes are also used. Briefly, in the method nucleic acids are stained with a fluorescent dye which can then be used to identify the nucleated cells by measurement of fluorescence on a flow cytometer. The improvement presented by this invention is the use of a saturating (or near saturating) amount of a nucleic acid dye, or mixture of dyes, which gives low fluorescence at excitation conditions, so as not to greatly interfere with the signals of the immunofluorescent dyes.
Abstract: In general, the invention provides methods for identifying genes involved in neurodegeneration and therapeutics for treating animals with a neurodegenerative disease. Methods and kits for the detection of compounds which enhance neuroprotection and diagnostic kits for the detection of neurodegenerative diseases are also a part of the invention.
Type:
Grant
Filed:
May 29, 1997
Date of Patent:
December 11, 2001
Assignee:
The General Hospital Corporation
Inventors:
Joshua M. Kaplan, Allison J. Oppenheimer, Anne C. Hart
Abstract: The invention provides novel polypeptides and polynucleotides encoding such polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such polypeptides to screen for antibacterial compounds.
Type:
Grant
Filed:
May 10, 1999
Date of Patent:
December 4, 2001
Assignee:
SmithKline Beecham Corp.
Inventors:
Martin Karl Russel Burnham, Michael Arthur Lonetto, Patrick Vernon Warren
Abstract: A ligand=mediated immunofunctional assay (LIFA) method for detecting the presence and the concentration of polypeptide hormone binding proteins which comprises capturing the binding protein with a solid phase bound first antibody, saturating the bound hormone binding protein with the ligand polypeptide hormone, and detecting the bound ligand polypeptide hormone with a detectably labeled second antibody specific for the ligand polypeptide hormone. In the absence of added saturating polypeptide hormone, the LIFA measures the amount of hormone binding protein bound in the endogenous ligand polypeptide hormone. A growth hormone binding protein assay illustrates the method of the present invention. LIFA assay results indicate that increased binding protein substantially increases growth hormone activity. Methods of use and formulation of growth hormone binding protein, growth hormone, insulin-like growth factor-1 and insulin-like growth factor binding protein are disclosed.
Type:
Grant
Filed:
May 15, 1995
Date of Patent:
December 4, 2001
Assignee:
Genentech, Inc.
Inventors:
Lena Mariana Susann Carlsson, Ross Graham Clark, Wai Lee Tan Wong